---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-23-000025"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:20:01.016286+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q3 net loss $9.3M; GPS Phase 3 enrollment complete, SLS009 shows CR in AML

## Summary
- Net loss $9.3M ($0.33/share) vs $7.0M in Q3 2022; cash $4.0M as of Sep 30, 2023; subsequent $4.0M offering.
- Phase 3 REGAL trial of GPS in AML expected to complete enrollment (ex-China) in November 2023; interim data late 2023/early 2024.
- SLS009 Phase 2a in AML: first patient achieved complete response, six of seven patients alive; anti-leukemic effects in all.
- FDA granted Orphan Drug Designation for SLS009 in AML and Fast Track for r/r PTCL.
- Anticipating $13.0M milestone from 3D Medicines upon China enrollment in REGAL in Q4 2023.

## SEC filing metadata
- accession: 0001390478-23-000025
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/0001390478-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/sls-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-23-000025
- JSON: https://secwatch.observer/filing/0001390478-23-000025.json
- Plain text: https://secwatch.observer/filing/0001390478-23-000025.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/0001390478-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.